Investigational Drug Information for Entinostat
✉ Email this page to a colleague
What is the drug development status for Entinostat?
Entinostat is an investigational drug.
There have been 70 clinical trials for Entinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 15th 2018.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are National Cancer Institute (NCI), Syndax Pharmaceuticals, and Merck Sharp & Dohme Corp.
There are four hundred and forty-three US patents protecting this investigational drug and four international patents.
Summary for Entinostat
US Patents | 443 |
International Patents | 4,763 |
US Patent Applications | 1,766 |
WIPO Patent Applications | 1,146 |
Japanese Patent Applications | 447 |
Clinical Trial Progress | Phase 2 (2018-05-15) |
Vendors | 120 |
Recent Clinical Trials for Entinostat
Title | Sponsor | Phase |
---|---|---|
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Entinostat
Top disease conditions for Entinostat
Top clinical trial sponsors for Entinostat
US Patents for Entinostat
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Entinostat | ⤷ Try a Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Try a Trial |
Entinostat | ⤷ Try a Trial | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | Signal Pharmaceuticals, LLC (San Diego, CA) | ⤷ Try a Trial |
Entinostat | ⤷ Try a Trial | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Try a Trial |
Entinostat | ⤷ Try a Trial | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Try a Trial |
Entinostat | ⤷ Try a Trial | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III | Frequency Therapeutics, Inc. (Woburn, MA) | ⤷ Try a Trial |
Entinostat | ⤷ Try a Trial | Liposomal compositions of epoxyketone-based proteasome inhibitors | Onyx Therapeutics, Inc. (Thousand Oaks, CA) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Entinostat
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Entinostat | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Try a Trial |
Entinostat | European Patent Office | EP3131552 | 2034-04-16 | ⤷ Try a Trial |
Entinostat | Spain | ES2823756 | 2034-04-16 | ⤷ Try a Trial |
Entinostat | Japan | JP2017514806 | 2034-04-16 | ⤷ Try a Trial |
Entinostat | Japan | JP2019070012 | 2034-04-16 | ⤷ Try a Trial |
Entinostat | Japan | JP2021059548 | 2034-04-16 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |